The UK government has unveiled a landmark National Cancer Plan for England that sets the course for transformative change in cancer care over the next decade. This strategy, launched on World Cancer Day, lays out bold goals for earlier diagnosis, faster treatment, expanded use of cutting-edge technologies and crucially, strong support structures for patients and their families.

At the heart of the plan is a striking survival ambition: by 2035, three in four people diagnosed with cancer will be either cancer-free or living well five years after diagnosis. That’s a leap from the current rate of about 60 %, and, if realised, could prevent hundreds of thousands of deaths and radically improve outcomes.

A cornerstone of this strategy is investment in diagnostics and technology. An additional £2.3 billion will deliver millions more screening and testing opportunities, while the use of robot-assisted surgery and genomic testing will be scaled up. This will help clinicians detect cancers earlier and tailor treatments based on the genetic profile of each tumour, strengthening personalised care pathways across cancer types.

What This Means for Osteosarcoma and Rare Cancers
While broad cancer-control strategies sometimes fall short of addressing rare and less common cancers, this plan explicitly recognises their unique challenges. For the first time in an England cancer strategy, rare and less common cancers, including bone cancers like osteosarcoma, are named as a priority, with commitments to improve diagnosis, increase access to specialist centres and expand research and trials for these groups.

For osteosarcoma, a disease where early detection is often difficult and specialised treatment essential, this framework reinforces several long-standing needs of the community:

• A stronger emphasis on rapid diagnosis pathways that help catch rare cancers earlier rather than as a late referral.
• Expansion of specialist multidisciplinary care centres where complex cases can be reviewed by teams with deep expertise.
• Greater access to genomic and molecular profiling that can inform more precise therapeutic choices.

These shifts align with decades of rare cancer advocacy calling for parity, not just in survival statistics but in research visibility and treatment innovation.

A Major Step for Families: Travel Costs Covered for Children and Young People with Cancer
One of the most heartfelt announcements tied to the Plan is a new £10 million annual fund to cover travel costs for children and young people (up to age 24) with cancer and their families, regardless of income. Many families face gruelling journeys to one of the limited number of specialist children’s cancer centres, often paying hundreds of pounds each month in fuel, parking or train fares. This support aims to ensure that no family has to delay or miss treatment because of the cost of getting there.

Health Secretary Wes Streeting emphasised that when a child is diagnosed with cancer, families should be able to focus on recovery not on whether they can afford petrol or bus tickets. 

This change is more than financial relief. It responds to lived experience: research shows a substantial proportion of families currently struggle with travel costs, with some missing appointments as a result. Removing this burden stands to improve both clinical outcomes and quality of life, especially for those navigating rare tumour pathways often centred in distant specialist hubs.

What Does This Mean For The Bardo Foundation and the Wider Rare Cancer Community
For patient organisations like us these developments open new advocacy and support horizons. The Plan’s explicit recognition of rare cancers provides a stronger policy lever to push for:

• Sustained investment in rare cancer research programmes, clinical trials and innovative therapeutics.
• Enhanced data capture and outcomes tracking for rare tumour subtypes.
• National awareness campaigns to reduce diagnostic delay, a critical issue in osteosarcoma where symptoms are often mistaken for injury or musculoskeletal pain.

The travel support announcement also underscores a broader shift toward holistic patient-centred care, something that aligns with our mission to support patients not just medically but socially, psychologically and financially.

This strategy does not solve all challenges overnight. Implementation, workforce capacity, equitable access to specialised care, and consistent funding will determine whether these ambitions truly translate into lived improvements. But for patients, families, clinicians and charities, the plan represents a significant step toward a future where cancer care is faster, fairer and more focused on quality of life, not just survival.